search
Back to results

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Primary Purpose

Turner Syndrome

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Lonapegsomatropin
Somatropin
Sponsored by
Ascendis Pharma Endocrinology Division A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Turner Syndrome

Eligibility Criteria

1 Year - 10 Years (Child)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Age between 1 and 10 years, inclusive. TS diagnosis via genetic test. Prepubertal status. Naïve to growth hormone therapy or growth hormone secretagogue. Exhibit impaired growth defined by at least one of the following: AHV< 6 cm/year or <25ᵗʰ percentile over a time span of 6-18 months for children of 2 years and older. Height (or length for individuals < 2 years old) <10ᵗʰ percentile for sex and age according to the 2000 CDC Growth Charts for the United States. Bone age within normal limits for chronological age, defined as no more than 20% above or below chronological age in months or delayed for chronological age (greater than 20% below chronological age), at screening. Biochemically euthyroid (including when on thyroid hormone supplementation). If on hormone replacement therapies for any hormone deficiencies other than growth hormone (e.g. adrenal, thyroid), must be on adequate and stable doses for ≥4 weeks prior to and throughout Screening. Fundoscopy at Screening without signs/symptoms of intracranial hypertension or proliferative retinopathy or evidence of any other retinal disease for which growth hormone therapy is contraindicated. Capable of giving signed informed consent. Participants and/or parents or legal guardians of participants must sign an informed consent statement. Assent should be obtained from all participants competent to understand the protocol, per IRB requirements. Exclusion Criteria: Turner Syndrome with presence of Y-chromosomal material on genetic testing and without a history of gonadectomy. Diagnosis of diabetes mellitus. Known history of clinically relevant conditions that may have an effect on growth, e.g. but not limited to celiac disease, malnutrition, treatment with potential growth-influencing medications for Attention-deficit/ hyperactivity disorder (ADHD), etc. Any known, clinically significant, congenital or acquired cardiac/cardiovascular dysfunction that might interfere with growth as determined by transthoracic echocardiogram. Known history or presence of malignancy. Individuals with history of intracranial tumor or cysts, with evidence of growth within the last 12 months prior to Screening. Note - Individuals with a history of intracranial tumor may be eligible if there is no evidence of residual tumor as determined by MRI/CT scan(s) performed within 6 to 12 months prior to screening. Hepatic transaminases (i.e., AST or ALT) above 3 times the upper limit of normal according to the central laboratory at screening. Major medical conditions and/or presence of contraindication to hGH treatment. Abnormal renal function. Clinically relevant systemic illness, acute critical illness, and complications following open heart surgery, abdominal surgery, multiple accidental traumas, acute respiratory failure, or similar conditions within 6 months prior to Screening. Poorly controlled hypertension. Receiving prior or concurrent treatment with any agent that might influence growth or interfere with GH secretion or action such as, but not limited to, non steroidal anabolic agents, sex steroids, etc. Oral/intravenous/intramuscular corticosteroids within 90 days prior to or throughout Screening. Known or suspected hypersensitivity to study intervention(s) or related products. Participation in any other trial involving an investigational compound within 90 days prior to Screening or in parallel to this trial. Any disease or condition that, in the judgement of the investigator, may make the individual unlikely to comply with the protocol or presents undue risk. Female who is pregnant, plans to be pregnant, or is breastfeeding.

Sites / Locations

  • Ascendis Pharma Investigational Site
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational Site
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational Site
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational Site
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational Site
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational Site
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational SiteRecruiting
  • Ascendis Pharma Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Lonapegsomatropin at 0.24 mg hGH/kg/week

Lonapegsomatropin at 0.30 mg hGH/kg/week

Lonapegsomatropin at 0.36 mg hGH/kg/week

Somatropin at 0.05 mg/kg/day

Arm Description

Lonapegsomatropin at 0.24 mg hGH/kg/week administered once-weekly by subcutaneous injection

Lonapegsomatropin at 0.30 mg hGH/kg/week administered once-weekly by subcutaneous injection

Lonapegsomatropin at 0.36 mg hGH/kg/week administered once-weekly by subcutaneous injection

Somatropin at 0.05 mg/kg/day administered once-daily by subcutaneous injection

Outcomes

Primary Outcome Measures

Annualized Height Velocity (AHV) (cm/year)
Calculated based on the difference between the AHV at 6 months and baseline

Secondary Outcome Measures

Annualized Height Velocity (AHV) (cm/year)
Calculated based on the difference between the AHVs at 12 and 24 months and baseline
Change from baseline in height standard deviation score (SDS)
Calculated based on the difference between the heights SDS at 6, 12, and 24 months and baseline.
Change from baseline in Bone age (calculated years)
Annual change in bone age measurements as per Gruelich-Pyle method
Change from baseline in ratio of bone age/chronological age
Calculated as a ratio

Full Information

First Posted
January 10, 2023
Last Updated
October 3, 2023
Sponsor
Ascendis Pharma Endocrinology Division A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05690386
Brief Title
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Official Title
New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 15, 2023 (Actual)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
October 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ascendis Pharma Endocrinology Division A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A 104 week dose finding open label trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus daily somatropin product in prepubertal individuals with Turner syndrome. Approximately 48 individuals (12 individuals per arm) will be randomized to receive one of three doses of lonapegsomatropin or a daily injection of somatropin. This is a trial that will be conducted in the United States.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Turner Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
An open label, parallel group with subjects randomized into 1 of 4 treatment groups (1:1:1:1)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lonapegsomatropin at 0.24 mg hGH/kg/week
Arm Type
Experimental
Arm Description
Lonapegsomatropin at 0.24 mg hGH/kg/week administered once-weekly by subcutaneous injection
Arm Title
Lonapegsomatropin at 0.30 mg hGH/kg/week
Arm Type
Experimental
Arm Description
Lonapegsomatropin at 0.30 mg hGH/kg/week administered once-weekly by subcutaneous injection
Arm Title
Lonapegsomatropin at 0.36 mg hGH/kg/week
Arm Type
Experimental
Arm Description
Lonapegsomatropin at 0.36 mg hGH/kg/week administered once-weekly by subcutaneous injection
Arm Title
Somatropin at 0.05 mg/kg/day
Arm Type
Active Comparator
Arm Description
Somatropin at 0.05 mg/kg/day administered once-daily by subcutaneous injection
Intervention Type
Biological
Intervention Name(s)
Lonapegsomatropin
Intervention Description
Once-weekly subcutaneous injection of Lonapegsomatropin
Intervention Type
Drug
Intervention Name(s)
Somatropin
Intervention Description
Once-daily subcutaneous injection of Somatropin
Primary Outcome Measure Information:
Title
Annualized Height Velocity (AHV) (cm/year)
Description
Calculated based on the difference between the AHV at 6 months and baseline
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Annualized Height Velocity (AHV) (cm/year)
Description
Calculated based on the difference between the AHVs at 12 and 24 months and baseline
Time Frame
52 weeks and 104 weeks
Title
Change from baseline in height standard deviation score (SDS)
Description
Calculated based on the difference between the heights SDS at 6, 12, and 24 months and baseline.
Time Frame
26 weeks, 52 weeks and 104 weeks
Title
Change from baseline in Bone age (calculated years)
Description
Annual change in bone age measurements as per Gruelich-Pyle method
Time Frame
52 weeks and 104 weeks
Title
Change from baseline in ratio of bone age/chronological age
Description
Calculated as a ratio
Time Frame
104 weeks
Other Pre-specified Outcome Measures:
Title
Insulin-like growth factor 1 (IGF-1) standard deviation score (SDS)
Description
Via Central Lab analysis
Time Frame
26 weeks, 52 weeks, and 104 weeks

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 1 and 10 years, inclusive. TS diagnosis via genetic test. Prepubertal status. Naïve to growth hormone therapy or growth hormone secretagogue. Exhibit impaired growth defined by at least one of the following: AHV< 6 cm/year or <25ᵗʰ percentile over a time span of 6-18 months for children of 2 years and older. Height (or length for individuals < 2 years old) <10ᵗʰ percentile for sex and age according to the 2000 CDC Growth Charts for the United States. Bone age within normal limits for chronological age, defined as no more than 20% above or below chronological age in months or delayed for chronological age (greater than 20% below chronological age), at screening. Biochemically euthyroid (including when on thyroid hormone supplementation). If on hormone replacement therapies for any hormone deficiencies other than growth hormone (e.g. adrenal, thyroid), must be on adequate and stable doses for ≥4 weeks prior to and throughout Screening. Fundoscopy at Screening without signs/symptoms of intracranial hypertension or proliferative retinopathy or evidence of any other retinal disease for which growth hormone therapy is contraindicated. Capable of giving signed informed consent. Participants and/or parents or legal guardians of participants must sign an informed consent statement. Assent should be obtained from all participants competent to understand the protocol, per IRB requirements. Exclusion Criteria: Turner Syndrome with presence of Y-chromosomal material on genetic testing and without a history of gonadectomy. Diagnosis of diabetes mellitus. Known history of clinically relevant conditions that may have an effect on growth, e.g. but not limited to celiac disease, malnutrition, treatment with potential growth-influencing medications for Attention-deficit/ hyperactivity disorder (ADHD), etc. Any known, clinically significant, congenital or acquired cardiac/cardiovascular dysfunction that might interfere with growth as determined by transthoracic echocardiogram. Known history or presence of malignancy. Individuals with history of intracranial tumor or cysts, with evidence of growth within the last 12 months prior to Screening. Note - Individuals with a history of intracranial tumor may be eligible if there is no evidence of residual tumor as determined by MRI/CT scan(s) performed within 6 to 12 months prior to screening. Hepatic transaminases (i.e., AST or ALT) above 3 times the upper limit of normal according to the central laboratory at screening. Major medical conditions and/or presence of contraindication to hGH treatment. Abnormal renal function. Clinically relevant systemic illness, acute critical illness, and complications following open heart surgery, abdominal surgery, multiple accidental traumas, acute respiratory failure, or similar conditions within 6 months prior to Screening. Poorly controlled hypertension. Receiving prior or concurrent treatment with any agent that might influence growth or interfere with GH secretion or action such as, but not limited to, non steroidal anabolic agents, sex steroids, etc. Oral/intravenous/intramuscular corticosteroids within 90 days prior to or throughout Screening. Known or suspected hypersensitivity to study intervention(s) or related products. Participation in any other trial involving an investigational compound within 90 days prior to Screening or in parallel to this trial. Any disease or condition that, in the judgement of the investigator, may make the individual unlikely to comply with the protocol or presents undue risk. Female who is pregnant, plans to be pregnant, or is breastfeeding.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ascendis Pharma
Phone
+1 650 352 8389
Email
NewInsiGHTSTrial@Ascendispharma.com
Facility Information:
Facility Name
Ascendis Pharma Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32827
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33701-4804
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55102
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Ascendis Pharma Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10017
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Withdrawn
Facility Name
Ascendis Pharma Investigational Site
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Ascendis Pharma Investigational Site
City
El Paso
State/Province
Texas
ZIP/Postal Code
79902
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Individual Site Status
Recruiting
Facility Name
Ascendis Pharma Investigational Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53211
Country
United States
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Learn more about this trial

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

We'll reach out to this number within 24 hrs